|
1
|
Parkin DM, Pisani P and Ferlay J:
Estimates of the worldwide incidence of 25 major cancers in 1990.
Int J Cancer. 80:827–841. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Koul H, Huh JS, Rove KO, Crompton L, Koul
S, Meacham RB and Kim FJ: Molecular aspects of renal cell
carcinoma: a review. Am J Cancer Res. 1:240–254. 2011.PubMed/NCBI
|
|
3
|
Patard JJ, Leray E, Rioux-Leclercq N,
Cindolo L, Ficarra V, Zisman A, De La Taille A, et al: Prognostic
value of histologic subtypes in renal cell carcinoma: a multicenter
experience. J Clin Oncol. 23:2763–2771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schachter LR, Cookson MS, Chang SS, Smith
JA Jr, Dietrich MS, Jayaram G and Herrell SD: Second prize:
frequency of benign renal cortical tumors and histologic subtypes
based on size in a contemporary series: what to tell our patients.
J Endourol. 21:819–823. 2007. View Article : Google Scholar
|
|
5
|
Rini BI, Vogelzang NJ, Dumas MC, Wade JL
III, Taber DA and Stadler WM: Phase II trial of weekly intravenous
gemcitabine with continuous infusion fluorouracil in patients with
metastatic renal cell cancer. J Clin Oncol. 18:2419–2426. 2000.
|
|
6
|
Yagoda A, Abi-Rached B and Petrylak D:
Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin
Oncol. 22:42–60. 1995.
|
|
7
|
Sarkar S and Suresh MR: An overview of
tuberculosis chemotherapy-a literature review. J Pharm Pharm Sci.
14:148–161. 2011.PubMed/NCBI
|
|
8
|
Billemont B, Méric JB, Izzedine H, et al:
Angiogenesis and renal cell carcinoma. Bull Cancer. 94:S232–S240.
2007.(In French).
|
|
9
|
Lainakis G and Bamias A: Targeting
angiogenesis in renal cell carcinoma. Curr Cancer Drug Targets.
8:349–358. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rini BI: VEGF-targeted therapy in
metastatic renal cell carcinoma. Oncologist. 10:191–197. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ahmad T and Eisen T: Kinase inhibition
with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res.
10:6388S–6392S. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Suárez Y and Sessa WC: MicroRNAs as novel
regulators of angiogenesis. Circ Res. 104:442–454. 2009.
|
|
13
|
Bridge G, Monteiro R, Henderson S, et al:
The microRNA-30 family targets DLL4 to modulate endothelial
cell behavior during angiogenesis. Blood. 120:5063–5072.
2012.PubMed/NCBI
|
|
14
|
Catto JW, Alcaraz A, Bjartell AS, et al:
MicroRNA in prostate, bladder, and kidney cancer: a systematic
review. Eur Urol. 59:671–681. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schaefer A, Jung M, Kristiansen G, et al:
MicroRNAs and cancer: current state and future perspectives in
urologic oncology. Urol Oncol. 28:4–13. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ru Y, Dancik GM and Theodorescu D:
Biomarkers for prognosis and treatment selection in advanced
bladder cancer patients. Curr Opin Urol. 21:420–427. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fendler A, Stephan C, Yousef GM and Jung
K: MicroRNAs as regulators of signal transduction in urological
tumors. Clin Chem. 57:954–968. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Weng L, Wu X, Gao H, et al: MicroRNA
profiling of clear cell renal cell carcinoma by whole-genome small
RNA deep sequencing of paired frozen and formalin-fixed,
paraffin-embedded tissue specimens. J Pathol. 222:41–51.
2010.PubMed/NCBI
|
|
19
|
Sinha S, Dutta S, Datta K, Ghosh AK and
Mukhopadhyay D: Von Hippel-Lindau gene product modulates TIS11B
expression in renal cell carcinoma: impact on vascular endothelial
growth factor expression in hypoxia. J Biol Chem. 284:32610–32618.
2009. View Article : Google Scholar
|
|
20
|
Hauser S, Wulfken LM, Holdenrieder S, et
al: Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p
and miR-378) as potential biomarkers in renal cell carcinoma.
Cancer Epidemiol. 36:391–394. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martínez-Salamanca JI1, Huang WC, Millán
I, Bertini R, Bianco FJ, Carballido JA, Ciancio G, Hernández C,
Herranz F, Haferkamp A, Hohenfellner M, Hu B, Koppie T,
Martínez-Ballesteros C, Montorsi F, Palou J, Pontes JE, Russo P,
Terrone C, Villavicencio H, Volpe A and Libertino JA; International
Renal Cell Carcinoma-Venous Thrombus Consortium. Prognostic impact
of the 2009 UICC/AJCC TNM staging system for renal cell carcinoma
with venous extension. Eur Urol. 59:120–127. 2011.PubMed/NCBI
|
|
22
|
Xu J, Wang B, Xu Y, et al: Epigenetic
regulation of HIF-1α in renal cancer cells involves HIF-1α/2α
binding to a reverse hypoxia-response element. Oncogene.
31:1065–1072. 2012.
|
|
23
|
Youssef YM, White NM, Grigull J, et al:
Accurate molecular classification of kidney cancer subtypes using
microRNA signature. Eur Urol. 59:721–730. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Esteban MA, Tran MG, Harten SK, et al:
Regulation of E-cadherin expression by VHL and
hypoxia-inducible factor. Cancer Res. 66:3567–3575. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Redova M, Poprach A, Besse A, et al:
MiR-210 expression in tumor tissue and in vitro effects of its
silencing in renal cell carcinoma. Tumour Biol. 34:481–491. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Skrzypek K, Tertil M, Golda S, et al:
Interplay between heme oxygenase-1 and miR-378 affects non-small
cell lung carcinoma growth, vascularization, and metastasis.
Antioxid Redox Signal. 19:644–660. 2013. View Article : Google Scholar
|
|
27
|
Chen LT, Xu SD, Xu H, Zhang JF, Ning JF
and Wang SF: MicroRNA-378 is associated with non-small cell lung
cancer brain metastasis by promoting cell migration, invasion and
tumor angiogenesis. Med Oncol. 29:1673–1680. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Lee DY, Deng Z, Wang CH and Yang BB:
MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis
by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA.
104:20350–20355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Jusufović E, Rijavec M, Keser D, et al:
let-7b and miR-126 are down-regulated in tumor tissue and correlate
with microvessel density and survival outcomes in non-small-cell
lung cancer. PLoS One. 7:e455772012.PubMed/NCBI
|
